A blood test based on immune system responses to testicular cancer identified the disease with high accuracy and detected most cases that would have been missed by standard laboratory markers, according to a new study published in Nature Communications.
Researchers at Mayo Clinic developed a diagnostic approach that analyzes patterns of circulating antibodies in blood rather than measuring tumor-derived proteins directly. The assay uses phage immunoprecipitation sequencing, a technology that screens for immune responses against thousands of protein fragments simultaneously, to identify a cancer-specific “immunosignature” associated with germ cell tumors.
The resulting test, known as GCT-iSIGN, was developed and validated using 427 serum samples, including samples from patients with testicular germ cell tumors and a broad range of control groups. The panel demonstrated strong diagnostic performance and correctly identified nearly all (23 of 24) cases lacking elevations in the conventional biomarkers alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase.
Current serum markers have been used for decades but frequently fail to detect disease, particularly in seminoma, the most common subtype. Normal marker results therefore cannot reliably exclude cancer, creating a need for additional tools that can support diagnosis before invasive procedures are undertaken.
Unlike existing blood-based approaches that search for tumor material circulating in the bloodstream, the new assay measures the host immune response. This strategy may offer practical advantages because antibodies are generally stable in blood and can remain detectable even when tumor burden is low. Notably, the test maintained diagnostic performance across different disease stages, suggesting that detection was not heavily dependent on tumor volume.
The study also demonstrated the potential for more refined disease classification. A second immunosignature panel showed an ability to distinguish seminoma from nonseminoma tumors, although its performance was not sufficient for use as a standalone diagnostic test.
While prospective validation will be required before clinical implementation, the results point to a potentially scalable and cost-effective route toward more sensitive blood-based testing for testicular cancer. If confirmed in future studies, immune-signature assays could complement ultrasound and conventional tumor markers, helping laboratories provide more reliable diagnostic information earlier in the patient pathway.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
